High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Pipeline Review, H2 2016', provides in depth analysis on High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted pipeline therapeutics. 

The report provides comprehensive information on the High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)
- The report reviews High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) Overview 6
Therapeutics Development 7
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Products under Development by Stage of Development 7
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Products under Development by Therapy Area 8
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Products under Development by Indication 9
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Pipeline Products Glance 10
Early Stage Products 10
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Products under Development by Companies 11
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Products under Development by Universities/Institutes 13
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 19
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Companies Involved in Therapeutics Development 21
Affibody AB 21
Bio3 Research S.r.l 22
Dicerna Pharmaceuticals, Inc. 23
Evec, Inc. 24
Ribomic Inc. 25
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Drug Profiles 26
Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Antisense RNAi Oligonucleotide to Inhibit HMGB1 for Liver Fibrosis - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CTR-1 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
CTR-2 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
CTR-3 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CTR-4 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
EV-007156 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Monoclonal Antibody to Inhibit HMGB1 for Brain Infarction, Influenza A Infections and Parkinson's Disease - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
RBM-005 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Recombinant Protein for Oncology - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Recombinant Protein to Inhibit HMGB1 for Stroke - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Dormant Projects 38
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Featured News & Press Releases 39
Nov 16, 2012: Bio3 Research Receives Hong Kong Patent For HMGB1 Antibodies To Treat Vascular Diseases 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Affibody AB, H2 2016 21
Pipeline by Bio3 Research S.r.l, H2 2016 22
Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016 23
Pipeline by Evec, Inc., H2 2016 24
Pipeline by Ribomic Inc., H2 2016 25
Dormant Projects, H2 2016 38